GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » Inventories, Inventories Adjustments

Zenith Capital (Zenith Capital) Inventories, Inventories Adjustments : $0.00 Mil (As of . 20)


View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital Inventories, Inventories Adjustments?

Zenith Capital's Inventories, Inventories Adjustments for the quarter that ended in . 20 was $0.00 Mil.


Zenith Capital Inventories, Inventories Adjustments Historical Data

The historical data trend for Zenith Capital's Inventories, Inventories Adjustments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital Inventories, Inventories Adjustments Chart

Zenith Capital Annual Data
Trend
Inventories, Inventories Adjustments

Zenith Capital Quarterly Data
Inventories, Inventories Adjustments

Zenith Capital Inventories, Inventories Adjustments Calculation

Inventories, Inventories Adjustments represents certain charges made in the current period in inventory resulting from breakage, spoilage, employee theft and shoplifting, etc.


Zenith Capital (Zenith Capital) Business Description

Industry
Traded in Other Exchanges
N/A
Address
300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1
Website
Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines